Stock Track | EyePoint Surges Over 5% on Positive Duravyu Clinical Updates

Stock Track

Oct 29, 2024

Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) soared by 5.12% on Monday, October 29th, as investors cheered the company's positive interim clinical data for its lead pipeline candidate Duravyu.

The rally was fueled by EyePoint's announcement of positive 16-week interim data from the ongoing Phase 2 VERONA study, evaluating Duravyu for the treatment of diabetic macular edema. Additionally, the company said it has dosed the first patient in the Phase 3 LUGANO study, investigating Duravyu for the treatment of wet age-related macular degeneration.

The encouraging clinical updates surrounding Duravyu, a potential treatment for major eye diseases, boosted investor confidence in EyePoint's prospects. Analysts at Chardan Capital reiterated their "Buy" rating on EYPT stock, reflecting optimism about Duravyu's development pathway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155560166"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155560166\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155560166?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155560166","market":"us","top_or_hot":-1,"title":"Stock Track | EyePoint Surges Over 5% on Positive Duravyu Clinical Updates","media":"Stock Track","content":"<p>Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) soared by 5.12% on Monday, October 29th, as investors cheered the company's positive interim clinical data for its lead pipeline candidate Duravyu.</p>\n\n<p>The rally was fueled by EyePoint's announcement of positive 16-week interim data from the ongoing Phase 2 VERONA study, evaluating Duravyu for the treatment of diabetic macular edema. Additionally, the company said it has dosed the first patient in the Phase 3 LUGANO study, investigating Duravyu for the treatment of wet age-related macular degeneration.</p>\n\n<p>The encouraging clinical updates surrounding Duravyu, a potential treatment for major eye diseases, boosted investor confidence in EyePoint's prospects. Analysts at Chardan Capital reiterated their \"Buy\" rating on EYPT stock, reflecting optimism about Duravyu's development pathway.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | EyePoint Surges Over 5% on Positive Duravyu Clinical Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | EyePoint Surges Over 5% on Positive Duravyu Clinical Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-29 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) soared by 5.12% on Monday, October 29th, as investors cheered the company's positive interim clinical data for its lead pipeline candidate Duravyu.</p>\n\n<p>The rally was fueled by EyePoint's announcement of positive 16-week interim data from the ongoing Phase 2 VERONA study, evaluating Duravyu for the treatment of diabetic macular edema. Additionally, the company said it has dosed the first patient in the Phase 3 LUGANO study, investigating Duravyu for the treatment of wet age-related macular degeneration.</p>\n\n<p>The encouraging clinical updates surrounding Duravyu, a potential treatment for major eye diseases, boosted investor confidence in EyePoint's prospects. Analysts at Chardan Capital reiterated their \"Buy\" rating on EYPT stock, reflecting optimism about Duravyu's development pathway.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"","article_id":"1155560166","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155560166","pubTimestamp":1730209218,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of EyePoint Pharmaceuticals  soared by 5.12% on Monday, October 29th, as investors cheered the company's positive interim clinical data for its lead pipeline candidate Duravyu.The rally was fueled by EyePoint's announcement of positive 16-week interim data from the ongoing Phase 2 VERONA study, evaluating Duravyu for the treatment of diabetic macular edema. Additionally, the company said it has dosed the first patient in the Phase 3 LUGANO study, investigating Duravyu for the treatment of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"Duravyu临床更新积极，股票跟踪EyePoint飙升超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) soared by 5.12% on Monday, October 29th, as investors cheered the company's positive interim clinical data for its lead pipeline candidate Duravyu.\nThe rally was fueled by EyePoint's announcement of positive 16-week interim data from the ongoing Phase 2 VERONA study, evaluating Duravyu for the treatment of diabetic macular edema. Additionally, the company said it has dosed the first patient in the Phase 3 LUGANO study, investigating Duravyu for the treatment of wet age-related macular degeneration.\nThe encouraging clinical updates surrounding Duravyu, a potential treatment for major eye diseases, boosted investor confidence in EyePoint's prospects. Analysts at Chardan Capital reiterated their \"Buy\" rating on EYPT stock, reflecting optimism about Duravyu's development pathway.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}